International Journal of Cancer · 1998 · 50 citations · 28 references
MedicineOncologyUrologyMetastasisMolecular OncologyUrologic OncologyBladder CancerImmunohistochemistryMalignant NeoplasmsMalignant TumorsMetastatic Urologic CancerUrothelial CarcinomaBiomarkers For Metastatic DiseaseBladder Tumor CharacterizationEpidermal Growth Factor Receptor SignalingImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingMetastatic Bladder Cancer
Bladder cancers frequently exhibit an increased number of epidermal growth factor receptors (EGFR) in comparison to normal urothelium. The EGFR could potentially be a target for toxic conjugates. The aim of our study was to compare the expression of EGFR in metastases with concurrent or primary tumour in the urinary bladder using immunohistochemical techniques and a monoclonal antibody. Tumour material from 20 patients was investigated. The majority (13/20) of the metastases were homogeneously stained and showed a moderate to strong membranous staining for EGFR. The expression of EGFR in primary bladder tumours and metastases was similar. There was no indication that tumour tissue exposed to chemotherapy or radiation had a decreased number of EGFR. Targeting of the EGFR thus seems potentially applicable to metastatic disease.
28
A.N.G. Clark, G. D. Mankikar, Ian Gray · The Lancet · 1975 · 690 citations
DavidE. Neal, M. Bennett, R R Hall et al. · The Lancet · 1985 · 608 citations
Noriaki Sugawa, A. Jonas Ekstrand, C. David James et al. · Proceedings of the National Academy of Sciences · 1990 · 594 citations